Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear
Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.
Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.